Aerpio Pharmaceuticals, Inc. (ARPO)
(Delayed Data from NSDQ)
$1.04 USD
+0.01 (0.96%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.04 USD
+0.01 (0.96%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News for May 29, 2020
by Zacks Equity Research
Companies In The News Are: ABIO, ARPO, LL, DLTR
Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks For May 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks For May 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
Aerpio Pharmaceuticals, Inc. (ARPO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.63, marking a +1.69% move from the previous day.
New Strong Buy Stocks for April 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Aerpio Pharmaceuticals, Inc. (ARPO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.
Has Aerpio Pharmaceuticals (ARPO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks For April 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Immunovant (IMVT) Catches Eye: Stock Jumps 5%
by Zacks Equity Research
Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Aerpio Pharmaceuticals, Inc. (ARPO) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Aerpio Pharmaceuticals, Inc. (ARPO) Rating Upgrade to Buy
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerpio (ARPO) Jumps: Stock Rises 7.8%
by Zacks Equity Research
Aerpio (ARPO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.